Biologic Drug Etanercept Shows Long-Term Safety in Children With Psoriasis

A new European study tracking children treated with etanercept, a biologic immunosuppressant, found the drug to be safe and effective over extended periods in real-world clinical settings. The findings could influence treatment guidelines and insurance coverage decisions for pediatric psoriasis, a condition affecting quality of life in thousands of young patients across Europe and North America.

Originaltitel: A long-term, prospective, observational cohort study of the safety and effectiveness of etanercept for the treatment of patients with paediatric psoriasis in a naturalistic setting